Alvotech And Fuji Stretch Alliance To Ustekinumab In Japan
Executive Summary
Alvotech and Fuji Pharma have extended their alliance to cover exclusive development and supply of biosimilar ustekinumab in Japan.
You may also be interested in...
Alvotech And Fuji Further Expand Biosimilars Partnership
Alvotech and Fuji Pharma have extended their strategic alliance for the commercialization of Alvotech biosimilars in Japan, adding a further early-stage candidate to the list of products covered by the deal that now encompasses six biosimilars.
Alvotech And Fuji Pharma Broaden Biosimilar Alliance In Japan
Longtime partners Alvotech and Fuji Pharma – the latter being a minority shareholder in the Icelandic firm – have extended their existing biosimilars partnership in Japan, as Alvotech continues to make strategic moves across the globe.
Meiji And Dong-A Start European Ustekinumab Trial
A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.